U.S. markets closed
  • S&P Futures

    4,268.50
    -12.50 (-0.29%)
     
  • Dow Futures

    33,631.00
    -87.00 (-0.26%)
     
  • Nasdaq Futures

    13,536.75
    -41.00 (-0.30%)
     
  • Russell 2000 Futures

    2,009.80
    -7.10 (-0.35%)
     
  • Crude Oil

    91.18
    -0.91 (-0.99%)
     
  • Gold

    1,810.80
    -4.70 (-0.26%)
     
  • Silver

    20.67
    -0.02 (-0.11%)
     
  • EUR/USD

    1.0248
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • Vix

    19.53
    -0.67 (-3.32%)
     
  • GBP/USD

    1.2114
    -0.0025 (-0.20%)
     
  • USD/JPY

    133.2820
    -0.1980 (-0.15%)
     
  • BTC-USD

    24,887.19
    +286.28 (+1.16%)
     
  • CMC Crypto 200

    594.81
    +23.53 (+4.12%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,830.90
    +283.92 (+0.99%)
     

Boston Scientific Buys Substantial Stake In Korean MedTech Player

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Boston Scientific Corporation (NYSE: BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures.

  • The deal is valued at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million.

  • M.I.Tech offers HANAROSTENT technology, a family of conformable, non-vascular, self-expanding metal stents, which Boston Scientific in Japan has distributed since 2015.

  • Non-vascular gastrointestinal and airway stents help clear occlusions or strictures in various areas of a patient's anatomy, including the biliary tree, pancreatic duct, esophagus, colon, and duodenum.

  • In many cases, stent placement is minimally invasive and may aid patient recovery faster than surgery.

  • The HANAROSTENT technology features a unique hook-cross nitinol design intended to provide a natural and flexible fit within a patient's anatomy and flared ends to help prevent stent migration.

  • The company expects to complete the transaction in 2H of 2022. The impact on GAAP and adjusted EPS is expected to be immaterial in 2022.

  • Price Action: BSX shares are up 3.19% at $36.36 during the market session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.